99m-Tc-sestamibi extrusion rate correlates with resistance to cytotoxic treatment and distant metastasis in non-small cell lung cancer

1997 ◽  
Vol 33 ◽  
pp. S230
Author(s):  
S. Koukouraki ◽  
M. Koukourakis ◽  
A. Giatromanolaki ◽  
A. Kapsoritakis ◽  
N. Karkavitsas
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Extrusion Rate ◽  
Cytotoxic Treatment

Thallium-201 SPECT in advanced non-small cell lung cancer: In relation with chemotherapeutic response, survival, distant metastasis and p53 status

2003 ◽  
Vol 17 (5) ◽  
pp. 369-374 ◽  
Author(s):  
Tevfik Fikret Çermik ◽  
Mahmut Yüksel ◽  
Celal Karlikaya ◽  
Latife Doĝanay ◽  
Mevlüt Türe ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Small Cell ◽  
Thallium 201 ◽  
Small Cell Lung ◽  
Chemotherapeutic Response ◽  
P53 Status

scholarly journals Interferon-Induced Transmembrane Protein 1 (IFITM1) Promotes Distant Metastasis of Small Cell Lung Cancer

2020 ◽  
Vol 21 (14) ◽  
pp. 4934
Author(s):  
Shuichi Sakamoto ◽  
Hiroyuki Inoue ◽  
Yasuko Kohda ◽  
Shun-ichi Ohba ◽  
Taketoshi Mizutani ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Transmembrane Protein ◽  
Small Cell ◽  
Small Cell Lung ◽  
Orthotopic Model ◽  
Metastatic Tumors ◽  
Metastatic Sites

Small cell lung cancer (SCLC) is a severe malignancy associated with early and widespread metastasis. To study SCLC metastasis, we previously developed an orthotopic transplantation model using the human SCLC cell line DMS273. In the model, metastatic foci were found in distant tissues such as bone and the adrenal gland, similarly as observed in patients with SCLC. In this study, we evaluated the differentially expressed genes between orthotopic and metastatic tumors in the model. We isolated tumor cells from orthotopic and metastatic sites, and the tumor cell RNA was analyzed using DNA microarray analysis. We found that 19 genes in metastatic tumors were upregulated by more than 4-fold compared with their expression in orthotopic tumors. One of these genes encodes a transmembrane protein, interferon (IFN)-induced transmembrane protein 1 (IFITM1), and immunohistochemical analysis confirmed the higher expression of the protein in metastatic sites than in orthotopic sites. IFITM1 was also detected in some SCLC cell lines and lung tumors from patients with SCLC. The overexpression of IFITM1 in DMS273 cells increased their metastatic formation in the orthotopic model and in an experimental metastasis model. Conversely, the silencing of IFITM1 suppressed metastatic formation by DMS273 cells. We also found that IFITM1 overexpression promoted the metastatic formation of NCI-H69 human SCLC cells. These results demonstrate that IFITM1 promotes distant metastasis in xenograft models of human SCLC.

Timing of chemotherapy in small cell lung cancer: A National Cancer Database analysis.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20076-e20076
Author(s):  
Shruti Bhandari ◽  
Danh Pham ◽  
Rohit Kumar ◽  
Jeremy T Gaskins ◽  
Goetz H. Kloecker
Keyword(s):  
Lung Cancer ◽  
Multivariate Analysis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Univariate Analysis ◽  
Small Cell ◽  
National Cancer Database ◽  
Small Cell Lung ◽  
Cytotoxic Treatment ◽  
Significant Difference

e20076 Background: Small cell lung cancer (SCLC) is an aggressive disease currently treated as soon as possible given its rapid doubling time. Evidence for appropriate timing of chemotherapy from diagnosis (TCD) for SCLC is lacking. This study evaluates TCD in SCLC on a national level. Methods: National Cancer Database identified SCLC patients treated with chemotherapy from 2010 - 2014. Factors associated with TCD were identified with multiple linear regression analyses. TCD was categorized into four groups using cutoff points of 7, 14, and 28 days. Using these categories, median overall survival (MOS) and log-rank test was used for univariate analysis of the survival outcome and the Cox model for multivariate analysis. Results: Among the 64491 SCLC, 42% received chemotherapy alone, 38% chemotherapy followed by radiation and 20% radiation followed by chemotherapy. Median TCD is 14 days with 21% treated within 7d, 21% 8-14d, 30% 15-28d and 28% > 28d from diagnosis. Age, race, insurance, comorbidities and stage were associated with TCD (Table). Significant difference in survival was found by TCD categories (P < .001). MOS for TCD within 7d was 8.2m, 8-14d was 9.2m, 15-28d was 10.3m, and > 28d was 10.8m. In the multivariate analysis, increased TCD was associated with better survival across all stages. Among stage IV patients, compared to those treated within 1 week, the HR is 0.92 (P < .001) for 1-2 weeks, HR 0.82 (P < .001) for 2-4 weeks, and HR 0.77 (P < .001) for > 4 weeks. Results are similar for Stage III and for Stage I/II. Conclusions: These results show a trend towards poor survival with early treatment. While we do not suggest delaying treatment for SCLC patients, our results provide new evidence to inform a discussion about appropriate treatment timing and individualizing treatment. Optimization of patients' clinical baseline before hasty cytotoxic treatment may lead to better outcomes. [Table: see text]

scholarly journals Assessment of surgical treatment for distant metastasis from completely resected non-small cell lung cancer

2007 ◽  
Vol 21 (1) ◽  
pp. 11-16 ◽  
Author(s):  
Tohru Hasumi ◽  
Nobuyuki Sato ◽  
Shinichirou Ohta ◽  
Masami Sato ◽  
Chiaki Endo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Effects of Vasculogenic Mimicry on Postoperative Recurrence and Progression of Non-Small Cell Lung Cancer

2021 ◽  
Vol 5 (4) ◽  
pp. 81-92
Author(s):  
Baoyong Ling ◽  
Aiqin Peng ◽  
Jijun You ◽  
Zhisheng Zhang ◽  
Weichun Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Local Recurrence ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Vasculogenic Mimicry ◽  
Postoperative Recurrence ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients

Vasculogenic mimicry (VM) in lung cancer shortens overall survival (OS) but its’ associations with postoperative recurrence and progression of early non-small cell lung cancer (NSCLC) remain unclear. The purpose of this study was to analyze the association of VM with postoperative recurrence and progression of NSCLC as well as the effect of VM on postoperative recurrence-free survival (RFS). This study included NSCLC patients and detected VM in surgical specimens. The associations of VM with the recurrence and progression were analyzed to assess the effect of VM on postoperative RFS in NSCLC. A total of 80 NSCLC cases were followed up for 3 years. During follow-up, 35 cases showed recurrence and progression where 5 (6.25%) cases had simple local recurrence and the other 30 (37.5%) cases had distant metastasis. The recurrence and progression rates in the first, second, and third years were 12.50%, 23.75%, and 7.50%, respectively. The median RFS was 14.2 months. VM was detected in 30 out of 80 cases and was significantly correlated with tumor differentiation (r = 0.365) and clinical stage (r = 0.374) (both, P = 0.001). Local recurrence of NSCLC was not correlated with VM, unlike distant metastasis (r = 0.598, P < 0.001). Average RFS was significantly longer in NSCLC patients without VM compared with the VM group 3 years post-operation (32 months versus 18 months, log-rank test P < 0.001). Considering these, VM is significantly correlated with postoperative distant metastasis of NSCLC in which it is of a certain value for predicting poor prognosis in NSCLC.

The benefits of a restaging PET scan after two cycles of neoadjuvant chemotherapy for resectable non-small cell lung cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17092-17092
Author(s):  
T. Tanvetyanon ◽  
E. Eikman ◽  
L. Robinson ◽  
E. Sommers ◽  
A. Cantor ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Ct Scan ◽  
Median Survival ◽  
Cell Lung Cancer ◽  
Distant Metastasis ◽  
Small Cell ◽  
Pet Scan ◽  
Small Cell Lung

17092 Background: Neoadjuvant chemotherapy can potentially improve the outlook of resectable non-small cell lung cancer (NSCLC). Whole-body 2-deoxy-2-[18F] fluoro-D-glucose (FDG)-PET is often used as an initial test to determine tumor resectability, but its role as a restaging test after neoadjuvant chemotherapy is unclear. Restaging PET after neoadjuvant chemoradiation helps identify unexpected distant metastasis and avoid unnecessary thoracotomy. We explored its benefits after neoadjuvant chemotherapy. Methods: Patients with stage IB-IIIA and selected IIIB resectable NSCLC received induction gemcitabine (1,000 mg/m2) and vinorelbine (25 mg/m2) on days 1, 8, 22, and 29. PET and CT scan were performed before enrollment and between day 43–50. Response from CT scan was defined by RECIST criteria; from PET, defined as >20% reduction in the SUVmax (a decrease of > 2 SD of spontaneous change in FDG uptake, previously validated). This abstract explores patients participated in a published prospective trial with available both pre- and post-treatment PET scans. Results: There were 19 patients: stage IB-7, stage IIB-2, and stage III-10. Median age was 67 years. Mean interval between staging and restaging PET scan was 59 days. By PET, 10 patients responded. By RECIST criteria, complete response occurred in 0, partial response in 6, and stable disease in 13 patients. Most successfully underwent a complete resection, but positive margins were present in 3; multi-station lymph node involvement was found intraoperatively in 1 patient. Overall median survival was 20.5 months. We found that restaging PET did not help identify any distant metastasis. Moreover, no survival difference was observed between PET responders and non-responders, though PET responders had more advanced stage than their counterparts: median survival 16 months vs. not reached (p = 0.08 adjusted for stage). PET response was correlated with RECIST response (p = 0.05) as well as the response as obtained by SUV max divided by the activity of contralateral lung or aorta ratio. Conclusion: Based on this small group of patients, a restaging PET scan obtained after two cycles of neoadjuvant chemotherapy among patients with resectable NSCLC did not appear to impact the decision on a planned thoracotomy. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document